Manufacture of pharmaceutical preparations
INSULIFE AS
Revenue 2024
NOK 56,000
Operating profit
NOK −13.0m
Equity
NOK 22.1m
Incorporated
2020
Share capital
NOK 72,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 56k | |
| Total operating costs | 13.1m | |
| Operating profit (EBIT) | −13.0m | |
| Net financial items | 119k | |
| Profit for the year | −12.9m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 28.7m | |
| of which current assets | 5.0m | |
| Equity | 22.1m | |
| Total liabilities | 6.6m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.